Armata Pharmaceuticals (ARMP) Short term Debt (2018 - 2026)
Armata Pharmaceuticals (ARMP) posted Short term Debt of $48.1 million for Q3 2025, up 43.78% sequentially from $33.4 million in Q2 2025, and up 16.28% YoY from $41.4 million in Q3 2024.
Armata Pharmaceuticals (ARMP) Short term Debt (2018 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Short term Debt for 5 years, with the latest figure at $48.1 million in Q3 2025.
- Quarterly Short term Debt rose 16.28% year-over-year to $48.1 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $48.1 million (up 16.28% YoY) and the FY2020 annual result came in at $1.9 million, up 100.0% from the prior year.
- Short term Debt rose to $48.1 million in Q3 2025 per ARMP's latest filing, from $33.4 million in the prior quarter.
- Over five years, Short term Debt peaked at $71.7 million in Q1 2024 and troughed at $27.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | Armata Pharmaceuticals | 171.61 Mn | 147.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 163.90 Mn |
| Sep 30, 2025 | 48.09 Mn |
| Jun 30, 2025 | 33.45 Mn |
| Mar 31, 2025 | 27.69 Mn |
| Sep 30, 2024 | 41.36 Mn |
| Jun 30, 2024 | 48.26 Mn |
| Mar 31, 2024 | 71.66 Mn |
| Dec 31, 2020 | 1.94 Mn |
| Sep 30, 2020 | 1.77 Mn |
| Jun 30, 2020 | 1.62 Mn |
| Mar 31, 2020 | 1.48 Mn |
| Dec 31, 2019 | 970,000.00 |
| Sep 30, 2019 | 885,000.00 |
| Jun 30, 2019 | 769,000.00 |
| Dec 31, 2018 | 970,000.00 |